Liraglutide Market

Liraglutide Market Size, Share & Industry Analysis, By Source:-(Pharmaceutical Manufacturers (Branded & Generic), Contract Manufacturing Organizations (CMOs), Research-Grade Suppliers.) By End-User:-(Pharmaceutical Industry, Hospitals & Clinics, Research Institutions) and Forecast, 2025-2035

The Liraglutide market is projected to grow at a CAGR of 7.8% from 2024 to 2032, driven by rising global rates of type 2 diabetes and obesity, along with expanding applications in weight management. Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the action of the endogenous incretin hormone. It enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, resulting in improved glycemic control and appetite regulation.

Liraglutide is marketed under brand names such as Victoza (for type 2 diabetes) and Saxenda (for chronic weight management), with proven cardiovascular benefits adding further to its clinical appeal. Growing endorsements from diabetes associations and clinical guidelines, along with increasing obesity prevalence and patient preference for once-daily injectable therapies, are major factors fueling the market’s expansion. Additionally, ongoing research into its use in pediatric obesity and non-alcoholic steatohepatitis (NASH) underscores potential for future growth.

Regionally, North America leads the Liraglutide market due to a high incidence of diabetes and obesity, widespread use of GLP-1 analogs, and favorable reimbursement frameworks. Europe follows, supported by strong regulatory approvals and patient access programs. The Asia-Pacific region is anticipated to witness the fastest growth, driven by increasing urbanization, changing lifestyles, and the rising prevalence of metabolic syndromes in countries like China, India, and South Korea.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

Introduction

Overview of Liraglutide
Key Applications & Industry Use Cases
Market Scope & Study Objectives

Market Overview

Global Market Size & Growth Trends (Historical & Forecast)
Market Value & Revenue Analysis
Demand-Supply Dynamics

Segmental Outlook

By Source
- Pharmaceutical Manufacturers (Branded & Generic)
- Contract Manufacturing Organizations (CMOs)
- Research-Grade Suppliers
Key End-Use Industries
- Pharmaceutical Industry.
- Hospitals & Clinics.
- Research Institutions.

Price Analysis

Current Price Trends (Per kg & Per Ton)
Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)

Production & Supply Volume

Global Production Capacity & Key Manufacturers
Production Process & Technological Developments
Raw Material Analysis

Trade Analysis (Import & Export)

Major Exporting & Importing Countries
Trade Volume & Value Statistics
Impact of Trade Regulations & Policies

Regional Analysis

North America (US and Canada)
Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
Rest of the World (Latin America, Middle East, and Africa)

Competitive Landscape

Top Global Manufacturers & Market Share
Company Profiles & Key Developments
Mergers, Acquisitions & Investments

Regulatory & Compliance Factors

FDA, REACH, and Other Regulatory Frameworks
Environmental & Safety Considerations
Emerging Policies Impacting Market Growth

Conclusion & Strategic Recommendations

Key Takeaways for Stakeholders
Market Entry Strategies

June 5, 2025

What is Liraglutide?

Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist used primarily to treat type 2 diabetes, obesity, and, more recently, for weight management in patients without diabetes. It mimics the action of GLP-1, a hormone that promotes insulin secretion, inhibits glucagon release, and slows gastric emptying, helping to lower blood sugar and reduce appetite. It is marketed under the brand names Victoza for diabetes and Saxenda for obesity. Liraglutide is administered via subcutaneous injection.

What is the market growth of Liraglutide?

The global Liraglutide market is projected to grow at a CAGR of 7.9% from 2025 to 2035, rising from USD 4.5 billion in 2025 to approximately USD 9.3 billion by 2035. Growth is driven by the increasing prevalence of obesity and type 2 diabetes, expanding indications for weight loss treatment, and the rising demand for GLP-1 receptor agonists as a preferred option in metabolic disease management.

What are the drivers of the Liraglutide market?

Key drivers include the rising global incidence of type 2 diabetes and obesity, which are driving demand for more effective, long-term treatment options. Liraglutide’s dual benefit in both diabetes management and weight loss enhances its appeal as a comprehensive treatment. Furthermore, the growing trend toward preventative healthcare and personalized medicine, coupled with positive clinical outcomes, has led to increasing adoption across developed and emerging markets.

Who are the key players operating in the Liraglutide market?

The primary player in the Liraglutide market is Novo Nordisk, the developer and manufacturer of Victoza and Saxenda. Other players in the GLP-1 receptor agonist space include Eli Lilly (with Trulicity), Sanofi (with Lyxumia), and Boehringer Ingelheim, who are also developing competitive GLP-1 receptor agonists for type 2 diabetes and weight loss.

Which region will exhibit the fastest growth in the Liraglutide market?

North America is expected to continue being the dominant market, driven by high healthcare spending, a strong patient population for both diabetes and obesity, and increasing insurance coverage for weight loss medications. Europe also shows strong demand for Liraglutide, particularly as obesity rates rise and more countries introduce weight management policies. Asia-Pacific is projected to exhibit the fastest growth due to rising healthcare access, urbanization, and increasing lifestyle-related disease prevalence in countries like China and India.

$1800/- Single User License
$3600/- Multi User License

Experienced in market research and consulting.
Seasoned professionals with diverse industry knowledge.
Proven track record in delivering valuable insights.
Tailored methodologies for unique client needs.
End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
Latest tools and tech for data collection, analysis, and visualization.
Embrace of AI and machine learning for deeper insights.
Global capabilities and extensive network.
In-depth understanding of international markets, trends, and regulations.
Dedicated to addressing specific client needs and goals.
Focus on delivering value through efficient research outcomes.

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com